Exclusive Advisory Agreement for COVID-19 and Host Cell Interactions Signed
Vancouver, Canada (March 25, 2020) – XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that an exclusive infectious disease advisory agreement (the “Agreement”) has been signed between XPhyto and Prof. Dr. Wolfgang Eisenreich. Prof. Dr. Eisenreich brings a unique and highly relevant set of skills to the XPhyto team and represents a swift and expanding investment on the part of the Company in the field of infectious disease, particularly COVID-19 (SARS-CoV-2).
“I look forward to working with the XPhyto group of companies, especially if we can make a positive impact on the current coronavirus situation and any other potential pandemic threats,” said Prof. Dr. Eisenreich. “I believe my scientific expertise and that of my team can add value to the task of better understanding how these viruses interact with human cells and ultimately to the development of clinical products.”
Prof. Dr. Eisenreich leads a research group at the Department of Chemistry, Technical University of Munich and the Central NMR Analytics Facility at Garching. He has over 20 years of experience in the study of metabolic pathways and signaling cascades as they relate to pathogen and host cell interactions. Prof. Dr. Eisenreich’s most recent work has focused on analysis and delineation of intracellular pathogenic bacteria and host cell interactions using innovative stable isotope labelling and profiling methodologies (NMR- and MS-based metabolomics). His technology driven analysis is a powerful tool in the study of pathogen and host cell interactions with a focus on host cell response. Prof Dr. Eisenreich’s work on metabolic adaptation between intracellular pathogens and their host cells was awarded the Max-von-Pettenkofer Prize in 2015. He and his team are well suited for the molecular analysis of coronavirus infections and related drug target identification and validation.
“The addition of Prof. Dr. Eisenreich and his unique skill set complements XPhyto’s infectious disease initiatives by potentially expediting the identification of specific targets for use in a rapid coronavirus detection platform and may play a role in the validation of natural anti-viral therapeutic agents, both announced on March 20, 2020,” said Hugh Rogers, CEO of XPhyto.
Media Inquiries North America
Mr. Knox Henderson
Media Inquiries Europe
MC Services AG
Julia Hofmann, Andreas Jungfer
T: +49 89 210 228 0